Claim 1: a method of treating a patient having a disease characterised by the deposition of AB,Which comprises administering to a patient in need of such treatment an effective amount of a compound that is (1R, R 1 ,4R) - 4 - methoxy - 5 - methyl - [5 - (6 - prop - 1 - in - 1 - il) pyridin-3-yl] - 3 - [h dispiro indeno - cyclohexane - 1,2 - 1 , 2 -] - 4 - imidazole Amine or its pharmaceutically acceptable Salt,In combination with an effective amount of an Antibody n3pglu AB.Claim 2: The Method according to claim 1, wherein the compound is a Salt of camsilate (1R, R 1 ,4R) - 4 - methoxy - 5 - methyl - [5 - (6 - prop - 1 - in - 1 - il) pyridin-3-yl] - 3 - [h dispiro indeno - cyclohexane - 1,2 - 1 , 2 -] - 4 - imidazole Amina.Claim 3: The Method according to claim 1 and 2,Wherein the anti AB Antibody n3pglu comprises a variable region of light chain (lcvr) and a variable region of heavy chain (hcvr), which includes the lcvr lcdr1,Lcdr2 and lcdr3 and hcvr includes hcdr1, hcdr2 and hcdr3 are selected from the group consisting of: (a) lcdr1 is SEQ ID no. 17, lcdr2 is SEQ ID no. 18, lcdr3 is SEQ ID no. 19, hcdr1 is SEQ ID no. 20Hcdr2 is SEQ ID no. 22, and hcdr3 is SEQ ID no. 23 and (b) lcdr1 is SEQ ID no. 17, lcdr2 is SEQ ID no. 18, lcdr3 is SEQ ID no. 19, hcdr1 is SEQ ID no. 21, hcdr2 is SEQ ID no. 22And hcdr3 is SEQ ID no. 24 (c) lcdr1 is SEQ ID no. 17, lcdr2 is SEQ ID no. 18, lcdr3 is SEQ ID no. 19, hcdr1 is SEQ ID no. 36, hcdr2 is SEQ ID no. 22, and hcdr3 is SEQ ID no. 37 (d) lcdr1 is SEQ ID no. 4Lcdr2 is SEQ ID no. 6, lcdr3 is SEQ ID no. 7, hcdr1 is SEQ ID no. 1, hcdr2 is SEQ ID no. 2, and hcdr3 is SEQ ID no. 3 e) lcdr1 is SEQ ID no. 4, lcdr2 is SEQ ID no. 5, lcdr3 is SEQ ID no. 7Hcdr1 is SEQ ID no. 1, hcdr2 is SEQ ID no. 2, and hcdr3 is SEQ ID no. 3.Claim: a compound that is 12 (1 r 1R, 4R) - 4 - methoxy 5 - methyl - [5 - (6 - prop - 1 - in - 1 - il) pyridin-3-yl] - 3 - H - dispiro [1,2 - indeno - cyclohexane 1,2 - imidazole] - 4 - Amine or its pharmaceutically acce
